Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
27 September 2019 | Story Ruan Bruwer | Photo Tania Allen
Netball
The Kovsies will face the Maties in the semi-finals of Varsity Netball in search of their fourth appearance in a final.
On Monday (30 September), the University of the Free State (UFS) netball team will have an ideal opportunity for revenge for what happened in this year’s Varsity Cup. In the semi-finals of the Varsity Cup back in April, the Shimla rugby team received a decent hiding from the Maties.

Now the UFS and Maties will face each other in another semi-final, this time in the netball version of the Varsity Cup, called Varsity Netball. The teams square off in the Callie Human Centre at 17:00.

Since losing to Tuks in the opening round, Kovsies have built up good momentum and confidence with six consecutive victories, including one over the Stellenbosch students on Monday (23 September). The score was 65-61.

The other wins were against UJ (69-35), TUT (64-20), NWU (59-55), Madibaz (70-41), and UWC (99-18), earning them the second spot on the log behind Tuks. The 99 goals against UWC were their best ever in the competition.The Free State women also won their encounter against Maties at this year’s USSA tournament by 38-31.

A victory would earn the team a shot at another Varsity Netball title. They have never lost a final, having appeared in three previous finals (2013, 2014, and 2018). Kovsies have won three of their previous five Varsity Netball semi-finals. They had met Maties only once before in a semi-final. This was last year in Bloemfontein when Kovsies prevailed by 56-45.
Khomotso Mamburu, goal defence of Maties, and Adéle Niemand, their assistant coach, both represented the Kovsies for many years.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept